Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tripelennamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.70 |
| ▸ | DRD1 | P21728 | 4/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.70 |
| ▸ | HTR2A | P28223 | 3/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrilamine SCHEMBL695041 | 0.91 | LMNA (0.83) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL4945522 | 0.88 | SMN1; SMN2 (0.81) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL9666725 | 0.87 | SMN1; SMN2 (0.82) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL9666718 | 0.87 | SMN1; SMN2 (0.82) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Tripelennamine SCHEMBL5432608 | 0.86 | CHRM2 (0.82) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Tripelennamine SCHEMBL17970 | 0.84 | CHRM2 (1.00) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Tripelennamine SCHEMBL29600775 | 0.84 | CHRM2 (1.00) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Chlorothen SCHEMBL1649730 | 0.84 | LMNA (0.71) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Tripelennamine SCHEMBL98916 | 0.83 | KDM4E (1.00) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Tripelennamine SCHEMBL1652325 | 0.83 | CHRM2 (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| EP-3565532-A1 | ORAL DISPERSIBLE FILM COMPOSITION | Bonayo Lifesciences Private Limited (IN) | 2019-11-13 | — | — | EP | claimed |
| US-20190336453-A1 | ORAL DISPERSIBLE FILM COMPOSITION | BonAyu Lifesciences Private Limited (IN) | 2019-11-07 | — | — | US | claimed |
| WO-2018127938-A1 | ORAL DISPERSIBLE FILM COMPOSITION | JUBELN LIFESCIENCES PVT. LTD. (IN) | 2018-07-12 | — | — | WO | claimed |
| EP-2431028-B1 | FAST-DISSOLVING ORAL FILM FOR EFFECTIVELY CONCEALING UNPLEASANT TASTES | CHABIO & DIOSTECH CO LTD (KR) | 2017-07-12 | — | — | EP | claimed |
| US-9561182-B2 | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals | CURE PHARMACEUTICAL CORPORATION (US) | 2017-02-07 | — | — | US | claimed |
| US-9492379-B2 | Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent | CHABIO & DIOSTECH CO., LTD. (KR) | 2016-11-15 | — | — | US | claimed |
| US-20150258058-A1 | Compounds For Enhancing Hypoxia Inducible Factor Activity And Methods Of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-17 | — | — | US | claimed |
| US-20150216819-A1 | AGENTS USEFUL FOR TREATING OBESITY, DIABETES AND RELATED DISORDERS | IXCHEL PHARMA, LLC (US) | 2015-08-06 | — | — | US | claimed |
| EP-0608322-B1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON VICKS INC (US) | 1998-07-22 | — | — | EP | claimed |
| US-5756118-A | CONSISTS OF AQUEOUS CARRIER, AN ANTIHISTAMINE DRUG AND NONIONIC POLYACRYLAMIDE BEING PREDISPERSED IN WATER-IMMISCIBLE OIL CONTAINING SURFACTANT HAVING HYDROPHILIC-LIPOPHILIC BALANCE ABOUT 7 TO 10 | RICHARDSON-VICKS INC. (US) | 1998-05-26 | — | — | US | claimed |
| EP-0608320-B1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON VICKS INC (US) | 1998-01-28 | — | — | EP | claimed |
| EP-0652774-B1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | PROCTER & GAMBLE (US) | 1997-05-07 | — | — | EP | claimed |
| US-5614178-A | TRANSDERMAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-03-25 | — | — | US | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216819-A1 | AGENTS USEFUL FOR TREATING OBESITY, DIABETES AND RELATED DISORDERS | GPR119, FABP4, ACAT1 | HRH1 4151/4885LMNA 1599/4885CHRM2 1397/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | HRH1 1389/4885LMNA 102/4885CHRM2 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.